Iovance Biotherapeutics (IOVA) EBIAT (2016 - 2025)
Historic EBIAT for Iovance Biotherapeutics (IOVA) over the last 13 years, with Q3 2025 value amounting to -$91.3 million.
- Iovance Biotherapeutics' EBIAT fell 923.14% to -$91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$397.7 million, marking a year-over-year increase of 300.1%. This contributed to the annual value of -$372.2 million for FY2024, which is 1617.82% up from last year.
- As of Q3 2025, Iovance Biotherapeutics' EBIAT stood at -$91.3 million, which was down 923.14% from -$111.7 million recorded in Q2 2025.
- In the past 5 years, Iovance Biotherapeutics' EBIAT registered a high of -$78.6 million during Q4 2024, and its lowest value of -$116.4 million during Q4 2023.
- Its 3-year average for EBIAT is -$103.2 million, with a median of -$107.4 million in 2023.
- As far as peak fluctuations go, Iovance Biotherapeutics' EBIAT soared by 3247.75% in 2024, and later tumbled by 1499.16% in 2025.
- Over the past 3 years, Iovance Biotherapeutics' EBIAT (Quarter) stood at -$116.4 million in 2023, then soared by 32.48% to -$78.6 million in 2024, then decreased by 16.12% to -$91.3 million in 2025.
- Its last three reported values are -$91.3 million in Q3 2025, -$111.7 million for Q2 2025, and -$116.2 million during Q1 2025.